An exception to the general conclusions regarding the tumor-promoting role of EP4 is in gastric carcinoma cell lines where administration of EP2 and EP4 agonists resulted in growth inhibition, decreased cell proliferation, and was accompanied by cAMP production. Here, PTGER4 is linked to gastric carcinoma.